Atai Life Sciences N.V. (NasdaqGM:ATAI) acquired remaining stake of DemeRx IB, Inc in October 2023.

Atai Life Sciences N.V. (NasdaqGM:ATAI) completed the acquisition of remaining stake of DemeRx IB, Inc. for $16 million in October 2023. Atai Life paid an initial cash consideration of $8 million to DemeRx, Inc. with the potential for earn-out consideration of up to an additional $8 million in the future upon the achievement of certain development milestones.